Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032463 (polycythemia vera)
 3,374 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a group of 172 cases of polycythemia vera treated with radioactive phosphorus acute granulocytic leukemia developed in 3 and chronic granulocytic leukemia in 6 cases. The author believes that development of acute granulocytic leukemia during this treatment may be considered with some probability as a result of the leukemia-inducing action of ionizing radiation. Transition of polycythemia vera into chronic granulocytic leukemia seems to be a natural outcome of this complex myeloproliferative syndrome in patients with survival prolonged by treatment with 32P.
Pol Med Sci Hist Bull
PMID:Observations on polycythemia vera turning into acute or chronic granulocytic leukemia during treatment with radioactive phosphorus 32P. 106 85

Using the biological test on rats the thrombocytopoietic activity (AT) was determined in sera of 13 patients with idiopathic thrombocytopenia (ITP), 5 patients with pancytopenia and bone marrow hypoplasia, 18 with thrombocytopenia developing during proliferative diseases of the haemopoietic system, and 4 patients with erythremia vera. A high mean thrombocytopoietic activity was demonstrated in ITP and this high activity was accounted for by significantly raised AT in acute thrombocytopenia. Increased AT was observed also in myeloproliferative syndromes associated with thrombocytopenia, while in pancytopenia with bone marrow hypoplasia and in erythremia vera AT seemed not increased independently of the stage of the disease. Greater number of cases will be necessary for drawing reliable conclusions.
Acta Haematol Pol
PMID:[Studies on the thrombocytopoietic factor. II. Determination of thrombocytopoietic activity in patients with hematological syndromes (preliminary study)]. 112 40

Clinical trials have shown that interferon (IFN) have myelosuppressive effects that can help reduce the uncontrolled clonal growth of hematopoietic cells in myeloproliferative disease. There are at least four diseases that are considered to be myeloproliferative disorders: chronic myelogenous leukemia, myelofibrosis polycythemia vera and idiopathic thrombocythemia. Recombinant IFN alpha has shown promise in inducing haematological and cytogenetic remission in some patients with chronic myelogenous leukemia. The exact role of IFN in prolonging the life of CML patients, however, remains to be determined in larger studies of longer duration. Preliminary evidence suggests that in myelofibrosis it may be more efficacious in the cellular than in fibrotic or osteosclerotic phase. IFN alpha has been reported to be of value in controlling excess platelet production in chronic myelogenous leukemia and idiopathic thrombocythemia as well as in reducing of red cell mas in polycythemia vera.
Acta Haematol Pol 1992
PMID:[Use of interferon in the treatment of chronic myeloproliferative disorders]. 148 70

We assessed the effect of phlebotomy on the proliferative activity of less (BFU-E) and more (CFU-E) mature bone marrow-derived erythroid progenitors from patients with polycythemia vera (PV) and polycythemia symptomatic (PS) in vivo in diffusion chamber culture. The cloning efficiency of erythroid progenitors under the effect of normal and increased erythropoietin (Epo) concentrations in PS was comparable with controls, whereas in PV the BFU-E and CFU-E-derived colony formation was significantly higher (p less than 0.01). In PV, the erythroid progenitors formed markedly more colonies in cultures stimulated with higher Epo concentration (p less than 0.01). The results of this study indicate that phlebotomy both in PV and PS does not affect the reactivity of erythroid progenitors to various Epo concentrations.
Pol Arch Med Wewn 1991 Sep
PMID:[Effect of bloodletting on the proliferative activity of erythroid progenitor cells from the bone marrow of patients with polycythemia and polycythemia vera]. 180 97

Microangiopathic haemolytic anaemia was diagnosed in the course of haematopoietic and lymphatic disorders such as chronic granulocytic leukemia, chronic myelofibrosis, chronic lymphatic leukemia, Osler's disease, chronic monocytic leukemia, and lymphoplasmocytic lymphoma, in 11 patients (6 women and 5 men) aged between 33 and 81 years (mean age 58.8 years) treated at the Haematological Out-Patient Clinic of the Postgraduate Medical Education Centre within 1977-1987. The following laboratory tests were carried out: 1) morphology of the peripheral blood and bone marrow, especially some haematological parameters concerning erythrocytes and blood platelets; 2) biochemical tests reflecting erythrocytes disintegration; 3) haemostasis. All examined patients suffered from haemolytic anaemia of various degree with characteristic changes in erythrocyte shape (helmets, tear-drops etc.). Haemolytic origin of anaemia was confirmed by the increased LDH activity. In the majority of patients no compensative stimulation of haematopoiesis (reticulocytosis, red blood cells hyperproliferation in bone marrow) was seen. Clinical symptoms of haemostatic disorders such as haemorrhagic diathesis and vein thrombosis were diagnosed in 50% of the patients. Blood platelet counts ranged from markedly decreased to significantly increased. Bone marrow smears did not show increased number of megacariocytes. Bleeding time was prolonged in the majority of examined patients while prothrombin index--decreased). Abnormal fibrinogen levels (decreased or increased) were found in the majority of patients with fibrin degradation products. Microangiopathic haemolytic anaemia in these patients differ from the typical Moschowitz's disease clinically probably due to the lack of compensative stimulation of erythropoiesis and lower thrombocytopenia.
Pol Tyg Lek 1989 Apr 03
PMID:[Microangiopathic hemolytic anemia in patients with diseases of the hematopoietic and lymphatic systems]. 262 5

The incorporation of other marrow cells into megakaryocytes, termed emperipolesis, has been studied in paraffin biopsy sections from 17 untreated patients with myeloproliferative disorders (MPDs). The group consisted of 12 females and 5 males, aged from 34 to 72 years (mean 51.3). Patients with essential thrombocythemia (ET)--9, chronic granulocytic leukemia (CGL)--4, polycythemia vera (PV)--3, and myelofibrosis (MF)--1 were included into the study. Clusters of large polyploid megakaryocytes were observed in anatomic relation to the marrow sinusoidal system. Emperipolesis has been scored as being present or absent per 100 megakaryocytes/slide. Cells found within megakaryocytes were mostly erythroblasts and mature granulocytes. The number of incorporated cells varied from 1 to 7 per one megakaryocyte. Considering the 17 patients with MPDs, emperipolesis was observed in a vast majority of those with ET(8/9) and PV(2/3), in some with CGL(1/4), but not in MF. The mechanism of megakaryocytic emperipolesis remains unclear. Adhesion molecules on megakaryocytes and incorporated cells may possible mediate the cell-to-cell interactions important for emperipolesis.
Acta Haematol Pol 1995
PMID:[Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders]. 765 23

The article presents clinical course analysis of essential thrombocythemia in 17 patients aged 29-82. The diagnostic criteria were the same as described by Polycythemia Vera Study Group. Mean platelet level of diagnosis was 1680 x 10(9)/l. Haemorrhagic complications were observed in 42% of the patients, while thrombotic ones or embolisms in 35%. In two cases both types of complications occurred. Asymptomatic course of the disease was observed in 5 patients. The statistical analysis proved that the patients with platelet count between 900-1900 x 10(9)/l are in danger of developing thrombotic episodes and thus antiaggregation treatment should be considered. If platelet level exceeds 1900 x 10(9)/l the risk of haemorrhage increases, so antiaggregation treatment is contraindicated and thrombocytapheresis is advised instead. The patients was started on treatment when platelet count was above 1000 x 10(9)/l in asymptomatic cases or with lower platelet level in symptomatic ones. The treatment consisted of busulphan, hydroxyurea or interferon alpha (in one of the patients) until lowering platelet level below 600 x 10(9)/l.
Pol Arch Med Wewn 1994 Aug
PMID:[Essential thrombocythemia--clinical course from personal material]. 780 May 86

Platelet abnormalities are common in patients with chronic myeloproliferative disorders. In this study we report abnormalities in platelets morphology and function in 45 patients with chronic myeloproliferative disorders: 15 with chronic myelogenous leukaemia (CML), 8 with polycythemia rubra vera (PRV), 20 with essential thrombocythemia, and 2 with myelofibrosis (ME). We investigated flow cytometric features of platelets as measured with Technicon H1 technology, VIZ, mean platelet volume (MPV), plateletocrit), platelet distribution width (PDW), and modal platelet volume (PLT Mode) Platelet aggregation in response to ADP, epinephrine and collagen was used as functional test. In patients with ET, PRV and MF we found a significant decrease in platelet volume (both MPV and PLT MODE). Decrease in platelet aggregation and secretion in response to ADP, epinephrine and collagen was the most frequent abnormality in platelets function and was observed in most of patients with thrombocythemia in chronic myeloproliferative disorders.
Acta Haematol Pol 1994
PMID:[Platelet defects in chronic myeloproliferative disorders]. 799 98

Since early eighties there have been several studies evaluating the effectiveness of biotherapy with natural and recombinant interferon alpha (IFN-alpha) in patients with proliferative hemocytopathies of both lymphoid and myeloid origin. In patients with hairy cell leukemia (HCL) interferon induces clinical and hematological remission and was considered for several years as the treatment of choice in the management of this disease. Subsequently it was found that IFN reveals myelosuppressive effect in patients with chronic myelogenous leukemia (CML) leading in majority of them to clinical and hematological remission and in part--cytogenetic one. Interferon decreases also thrombocytosis and its thrombotic-haemorrhagic complications in patients with essential thrombocythemia (ET) and decreases erythrocyte count in patients with polycythemia rubra vera (PRV).
Acta Haematol Pol 1994
PMID:[Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders]. 806 97

The activity of glucose-6-phosphate dehydrogenase (G6PD), glutathione reductase (GSSG-R), glutathione peroxidase (GSH-Px) and MDA levels have been assayed in red blood cells (RBC), obtained from 57 people suffering from haemoblastoses. The activities of G6PD in the RBC in patients with polycythemia vera (PV) and chronic lymphoid leukemia (CML) are significantly higher than those in healthy patients. Changes in the activity of glutathione dependent enzymes GSSG-R and those of GSH-Px in the RBC go in opposite directions: the activity of GSSG-R is significantly enhanced in patients with PV and CML, but the activity of GSH-Px is decreased in all patients suffering from haemoblastoses. The high levels of MDA in the RBC of all patients with haemoblastoses indicate intensification of lipid peroxidation in their RBC.
Mater Med Pol
PMID:The activity of glucose-6-phosphate dehydroxygenase and glutathione enzymes in red blood cells in patients with haemoblastoses. 856 75


1 2 3 Next >>